- New ETFs
- Bond ETFs
- Currency ETFs
- Emerging Market ETFs
- Commodity ETFs
- Broad U.S. Equity ETFs
- Sector ETFs
- Specialty ETFs
JPMorgan Upgrades Ariad Pharmaceuticals, Inc. To Overweight
Recent Articles by Benzinga Staff
- Doug Kass Presses His Shorts (SPY, QQQQ)
- eTrade Gets Sued - Is Lohan the Milkaholic? (ETFC)
- Download Every Movie Ever Made in 4 Minutes (CSCO)
- Q & A From Cisco Press Release
- Cisco To Go From Technology "Plumber" to Business Partner
Analyst Color
- Comerica Incorporated (CMA) Prices Its Offering At $35
- TransMontaigne Partners L.P. (TLP) Maintains A Hold Rating
- Susquehanna Bancshares, Inc. (SUSQ) Plans To Raise $300 Million
- Starwood Property Trust, Inc. (STWD) Maintains A Buy Rating
- PartnerRe Ltd.’s (PRE) Losses In Chile Expected To Severely Impact the First-Quarter
Upgrades
- Benzinga’s Top Upgrades (MAT, YGE, COMV, DNR, ARRS)
- HNT Upgraded To Market Perform
- LNCE Upgraded To Buy At BB&T
- Cowen Upgrades UTX To Outperform
- Potash (POT) Upgraded Fertilizer Stocks Set to Move
Price Target
- Citigroup In Favour Of Cadbury’s Acquisition By KFT
- Macy’s, Inc. (M) Upgraded To Buy; Price Target Raised
- Southern (SO) Looks Good In The Long Term
- FBR Capital Markets Upgrades PNC Financial Services Group (PNC) And Raises Price Target
- Collins Stewart Lowers Solarfun Power Holdings (SOLF) Price Target
Analyst Ratings
- Comerica Incorporated (CMA) Prices Its Offering At $35
- TransMontaigne Partners L.P. (TLP) Maintains A Hold Rating
- Susquehanna Bancshares, Inc. (SUSQ) Plans To Raise $300 Million
- Starwood Property Trust, Inc. (STWD) Maintains A Buy Rating
- PartnerRe Ltd.’s (PRE) Losses In Chile Expected To Severely Impact the First-Quarter
Posted on 11/09/09 at 6:59am by Benzinga Staff
JPMorgan upgrades Ariad Pharmaceuticals, Inc. (Nasdaq: ARIA) to Overweight. The JPMorgan analyst raised ARIA price target to $6, Ariad closed just above $2 on Friday.
On JPMorgan's upgrade, Ariad Pharmaceuticals is trading up in the pre-market. The JPMorgan analyst raised his price target ahead of Ariad'spivotal late-stage data on sarcoma drug.
Bookmark/Search this post with:
Related Articles
Today's Trading Ideas
Featured Articles
Related News from the Stock Market
- Curious Positioning in Ariad
- Benzinga’s Top Pre-Market Gainers (OSIP, BIOD, ARIA, RMTI, DISH)
- Benzinga’s Top Pre- Market Losers (ASBC, MNKD, HOGS, AIXG, ARIA, ICXT)
- Barclays Continue With Their Overweight Call For ARIAD Pharmaceuticals (ARIA)
- Benzinga’s Top Pre- Market Gainers (ZILG, YONG, GERN, ARIA, XLNX)
There are 0 comments
Please note that comments may take up to one hour before they get published on the site. Please check back later to see your comments.
Post new comment
Receive Benzinga's Best 2010 Stock Idea!
